Establishment Labs Holdings Inc.
ESTA Nasdaq
SEC CIK 1688757
Follow Establishment Labs
Weekly email: filings, results
Revenue, last quarter
$72M
+33.9% vs same quarter last year
Net income
−$10.7M
+3.9% vs same quarter last year
EPS, diluted
−$0.35
+7.9% vs same quarter last year
Operating cash flow
$7.7M
+168.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $211.1M | −$51.1M |
| FY24 | $166M | −$84.6M |
| FY23 | $165.2M | −$78.5M |
| FY22 | $161.7M | −$75.2M |
| FY21 | $126.7M | −$41.1M |
| FY20 | $84.7M | −$38.1M |
| FY19 | $89.6M | −$38.2M |
| FY18 | $61.2M | −$21.1M |
| FY17 | $34.7M | −$34.9M |
| FY16 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 69.3% | −18.5% | −24.2% |
| FY24 | 66% | −30.1% | −51% |
| FY23 | 64.8% | −39.4% | −47.5% |
| FY22 | 65.9% | −24.5% | −46.5% |
| FY21 | 67.4% | −19.8% | −32.5% |
| FY20 | 62% | −33% | −45% |
| FY19 | 61.3% | −34.5% | −42.6% |
| FY18 | 59% | −39% | −34.5% |
| FY17 | 51% | −57.6% | −100.6% |
| FY16 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$56.9M |
| FY24 | −$64.6M |
| FY23 | −$96.4M |
| FY22 | −$55M |
| FY21 | −$30M |
| FY20 | −$14.6M |
| FY19 | −$36.3M |
| FY18 | −$35.6M |
| FY17 | −$32.9M |
| FY16 | - |
- Establishment Labs
- Healthcare median
Show the numbers
| Year | Establishment Labs | Healthcare median |
|---|---|---|
| FY25 | −24.2% | −30.6% |
| FY24 | −51% | −47% |
| FY23 | −47.5% | −58% |
| FY22 | −46.5% | −80.4% |
| FY21 | −32.5% | −71.9% |
| FY20 | −45% | −62.2% |
| FY19 | −42.6% | −46.3% |
| FY18 | −34.5% | −49.6% |
| FY17 | −100.6% | −45.9% |
| FY16 | - | −36% |